Advertisement
Advertisement
Dr Utz Claassen, chairman of the executive board and CEO, Syntellix

Syntellix introduces bioabsorbable magnesium alloy implants in Asia

  • Syntellix has aided thousands of patients in many countries with MAGNEZIX, winning multiple top innovator awards
Supported by:Discovery Reports

While medical technology beholds daily discoveries, few of them are considered as compelling a breakthrough as bioabsorbable metal implants. Single-handedly revolutionising and championing a new market of approved metallic transformable implants, Syntellix Asia offers orthopaedic, trauma, and in the near future, neurosurgery and dental patients a faster, more cost-effective and safer recovery process through its bioabsorbable metallic magnesium implant product, MAGNEZIX.

Established in 2008 in Germany, Syntellix has aided thousands of patients in many countries with MAGNEZIX, winning multiple top innovator awards including the prestigious Innovation Award of the German Economy – The World’s First Innovation Award. This world-renowned disruptive breakthrough comes in numerous forms such as pins and screws for various kinds of surgeries, and is the first bioabsorbable orthopaedic metallic implant material to acquire CE marking and product registration in countries such as Australia, Singapore, Indonesia and Israel.

The bioabsorbable, yet durable, stable and elastic nature of MAGNEZIX eliminates the need for patients to endure a second surgery for metal removal. This results in less pain, less infection risks, less cost and less time expended, while hastening the healing process as magnesium verifiably stimulates bone growth, outclassing titanium and steel implants. Surgeons who use this product likewise save resources and time, while helping their customers achieve maximum restorative results.

“I am personally convinced that we have, by far, the best implant technology in the world,” says Dr Utz Claassen, chairman of the executive board and CEO of Syntellix. “No country can benefit more from these advantages than China with its more than 1.5 billion people.”

In line with the company’s vision of MAGNEZIX being used by hospitals and surgeons all over Asia, Singapore-based Syntellix Asia has formed strong connections with leading hospitals and universities in the country and in the region. Syntellix works with more than 50 partners worldwide, and seeks to form more Asian partnerships with distributors in mainland China, India, Hong Kong, Indonesia, Thailand, Japan and South Korea.

Post